MYGN vs QDEL
Myriad Genetics, Inc. and QuidelOrtho Corp., side by side — 6 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | MYGN | QDEL |
|---|---|---|
| Revenue | $824.5M | $2.7B |
| Net income | $-365.9M | $-1.1B |
| Gross margin | 69.9% | — |
| Net margin | −44.4% | −41.5% |
| Return on equity | −68.5% | −46.1% |
| Diluted EPS | −$3.95 | −$16.69 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | $-151.6M | $-83.0M |
| Equity | $368.0M | $1.9B |
| Net debt / equity | −0.08× | 1.41× |
| Current ratio | 2.49× | 1.50× |
| Revenue CAGR 5y | 8.2% | 10.4% |
| Profit CAGR 5y | — | — |
QDEL bills 3.3× the revenue of MYGN, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
6 years side by side
| Fiscal year | MYGN | QDEL |
|---|---|---|
| FY2025 | $824.5M | $2.7B |
| FY2024 | $837.6M | $2.8B |
| FY2023 | $753.2M | $3.0B |
| FY2022 | $678.4M | $3.3B |
| FY2021 | $690.6M | $1.7B |
| FY2020 | $557.1M | $1.7B |
Net income by year
Bottom line
| Fiscal year | MYGN | QDEL |
|---|---|---|
| FY2025 | $-365.9M | $-1.1B |
| FY2024 | $-127.3M | $-2.1B |
| FY2023 | $-263.3M | $-10.1M |
| FY2022 | $-112.0M | $548.7M |
| FY2021 | $-27.2M | $704.2M |
| FY2020 | $-223.6M | $810.3M |
Advertisement
AdSense · Rectangle 336×280
More in this industry